China Achieves Curie-Scale Domestic Production Breakthrough for Medical Alpha-Isotope Actinium-225
Core Breakthrough: Curie-Scale Industrial Production of Alpha Emitters Achieved—Breaking the Global Supply “Choke Point”
For years, stable supply of medical alpha-emitting isotopes—such as actinium-225 (²²⁵Ac), bismuth-213 (²¹³Bi), and thorium-227 (²²⁷Th)—has been highly concentrated among a handful of Western institutions: the U.S. Oak Ridge National Laboratory (ORNL), Germany’s Institute for Transuranium Elements (ITG), and Canada’s TRIUMF accelerator centre collectively account for over 92% of global clinical-grade ²²⁵Ac production capacity. Constrained by formidable technical barriers—including extremely short half-lives (10 days for ²²⁵Ac), ultra-high-purity separation challenges, and stringent neutron flux requirements—Chinese radiopharmaceutical enterprises have long relied entirely on imported raw materials. A single batch of ²²⁵Ac commands a procurement price of USD 800,000–1,200,000, with delivery lead times stretching 3–6 months—severely impeding clinical translation and large-scale adoption of Targeted Alpha Therapy (TAT).
In Q3 2024, China’s first domestically developed, curie-scale (≥1 Ci, i.e., 3.7 × 10¹⁰ Bq) clinical-grade ²²⁵Ac manufacturing platform passed the National Medical Products Administration’s (NMPA) Good Manufacturing Practice (GMP) compliance inspection for radiopharmaceuticals in Mianyang, Sichuan Province. This milestone marks China as only the third country globally capable of reliably supplying clinical-grade alpha emitters. The production line employs an indigenous process combining “high-flux reactor irradiation” with “multi-stage ion-exchange chromatography purification.” Each batch delivers 1.2–1.5 Ci of high-purity ²²⁵Ac (radiochemical purity >99.95%; metallic impurities <10⁻⁹ mol/g), achieving a yield rate of 83%—12 percentage points higher than current international benchmarks.
Cost Restructuring: Clinical Drug Prices Plummet—Driving the “Affordability Inflection Point”
The scale-up breakthrough has triggered a fundamental reset across the pricing chain. According to a third-party cost model disclosed by the Center for Drug Evaluation (CDE) under China’s NMPA, the domestic production cost of ²²⁵Ac has fallen to USD 180,000–220,000 per curie—a 63%–76% reduction versus average import prices. This cost advantage cascades directly to end products: For instance, the domestically manufactured ²²⁵Ac-PSMA-617 injection—currently in Phase III clinical trials—is projected to cost RMB 280,000–350,000 per treatment course (4–6 cycles), representing over a 64% reduction compared to the current parallel-import price of Pluvicto® (EMA-approved in Europe) in China (~RMB 980,000/course). Crucially, reliable domestic supply eliminates the prior “drug available but no isotope” bottleneck: Top-tier hospitals previously had to suspend patient enrollment in TAT trials due to isotope shortages; now, monthly rolling deliveries have shortened multi-center clinical trial timelines by 40%, accelerating expansion into new indications—including ²²⁵Ac-DOTATATE for neuroendocrine tumors and ²²⁵Ac-J591 for prostate cancer bone metastases. As noted by an expert involved in the national radiopharmaceutical special project review: “Once per-course costs enter the reasonable range for China’s national health insurance negotiations (<RMB 500,000) and supply reliability exceeds 95%, targeted alpha therapy will truly transition from an ‘elite-hospital premium service’ to a routine therapeutic option at regional medical centers.”
Production-Line Leap: Accelerator Cluster Construction Accelerates Toward Million-Dose Ecosystem
The curie-scale milestone is merely the starting point. Of even greater strategic significance, construction of China’s first “hundred-curie-scale dedicated alpha-isotope production facility”—a joint initiative led by China National Nuclear Corporation (CNNC), the Chinese Academy of Sciences’ Institute of Modern Physics, and Hengrui Medicine—began civil works in Lanzhou New Area in October 2024. At its core are two high-intensity proton cyclotrons (300 MeV / 100 kW, designed beam current: 2.5 mA), integrated with fully automated hot-cell separation systems and an AI-powered radioactive quality monitoring platform. Upon completion, the facility will achieve annual ²²⁵Ac output of ≥100 Ci—equivalent to over 1.2 million clinical doses—and will simultaneously support production of other alpha emitters, including ²¹³Bi and ²²⁷Th. Notably, this infrastructure is not isolated but deeply embedded within China’s national nuclear technology application industrial strategy. Its ripple effects are already catalyzing three major investment themes:
• CDMO Service Upgrade: Companies including United Imaging Healthcare (Shanghai) and Dongcheng Pharmaceutical have signed agreements to build GMP-compliant alpha-radiopharmaceutical conjugation platforms offering end-to-end services—from isotope receipt and chelation labeling to sterile dispensing.
• Targeting Vector Innovation: To address the ultrashort path length of alpha particles (47–85 μm), domestic nanomedicine firms—including Suzhou NanoMicro and Shenzhen Chipscreen Biosciences—are rapidly developing high-affinity PSMA-targeting small-molecule mimetic peptides and novel DOTA-derivative ligands to enhance tumor cell uptake.
• Clinical CRO Specialization: Nuclear medicine–focused CROs—such as PAREXEL Beijing and Burning Rock Biotech (Guangzhou)—are establishing full-service capabilities spanning dosimetry modeling, microdose PET validation, and alpha-radiation biological effect assessment. According to research by Zero2IPO, total investment and financing in China’s alpha-radiopharmaceutical industry is projected to exceed RMB 30 billion (USD ~4.2 billion) between 2025 and 2027—with nearly 60% allocated to these three subsectors.
Global Impact: Regulatory Standard Competition Emerges—“China’s Approach” May Become the New Paradigm
This leap in production capability is compelling adjustments to international regulatory frameworks. Currently, the U.S. FDA and European Medicines Agency (EMA) continue applying existing Chemistry, Manufacturing, and Controls (CMC) guidelines—developed for beta emitters like ⁹⁰Y and ¹⁷⁷Lu—to alpha therapeutics, without defining specific limits for metallic impurities in ²²⁵Ac or stipulating required frequencies for daughter nuclide equilibrium monitoring. In contrast, China’s NMPA issued the “Technical Guidance Principles for Alpha-Emitting Radiopharmaceuticals (Draft for Comments)” in September 2024—the first such document globally—explicitly mandating:
① Total radioactivity of daughter impurities (e.g., ²²¹Fr, ²¹⁷At) in raw material must be <0.1%;
② Dynamic daughter-nuclide equilibrium verification must be performed over 72 hours for every batch;
③ Conjugated products must undergo real-time residual-free-²²⁵Ac monitoring using microfluidic chip technology.
This “China Standard”—stricter than those in Europe and the U.S.—is drawing attention from international regulatory agencies. Multiple experts participating in discussions at the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) report that China has formally submitted a proposal to establish an ICH working group exclusively for alpha-emitting radiopharmaceuticals. If successful, this would not only elevate China’s voice in global radiopharmaceutical standard-setting but could also prompt multinational pharmaceutical companies to reconfigure their global supply chains: Future alpha therapeutics targeting the Asia-Pacific market may prioritize Chinese-sourced isotopes and align with China’s standards—effectively establishing China as a de facto “regional regulatory hub.”
Hard-Tech Foundation: Policy-Capital Synergy Enables Clear Commercial Pathway
This breakthrough is no accident. It rests on sustained support from China’s “14th Five-Year Plan” Nuclear Technology Application Special Program, major scientific instrument development projects funded by the National Natural Science Foundation of China, and the Shanghai Stock Exchange’s STAR Market “Category V” listing criteria—which specifically incentivize medical device enterprises possessing demonstrable, high-barrier technologies. In 2024, China’s Ministry of Finance further added “medical isotope self-reliance” to the list of advanced manufacturing sectors eligible for VAT additional deduction incentives.
From a commercial perspective, alpha radiopharmaceuticals exhibit the classic “high-barrier–high-margin–high-stickiness” profile: gross margins per dose exceed 85%; patients require multiple administrations, ensuring recurring revenue; and robust clinical data confirm survival benefits in late-stage, treatment-refractory cancers (e.g., median overall survival of 15.3 months for mCRPC patients treated with ²²⁵Ac-PSMA—6.8 months longer than standard care). With the first hundred-curie production line slated to commence operations in 2026 and the first domestically produced alpha radiopharmaceuticals expected to receive NMPA marketing authorization by end-2025, a new precision radiotherapy赛道 (track) valued in the hundreds of billions of RMB is rapidly taking shape in China—not merely a triumph of technological self-reliance, but a powerful validation of a hard-tech industrialization paradigm grounded firmly in clinical value.